TenNor Therapeutics (China)

TenNor Therapeutics (6872.HK) was incorporated in 2013 and is a biotech company approaching the commercialization stage, focused on discovering, developing and commercializing differentiated innovative drug products to address unmet clinical needs in bacterial infections and bacteria-related metabolic diseases. Using its independently developed multi-target conjugated molecule technology, it aims to provide optimal treatment options. As of June 30, 2026, the company had built a pipeline of eight innovative programs, including two core products: rifasutenizol (TNP-2198), a multi-target conjugated new molecular entity (NME) candidate used in combination with amoxicillin and a proton pump inhibitor for Helicobacter pylori infection and also as monotherapy for bacterial vaginosis and Clostridioides difficile infection; and rifaquizinone (TNP-2092 injection), a three-target NME candidate for acute bacterial skin and skin structure infections and implant-associated bacterial infections such as prosthetic joint infection, left ventricular assist device infection and central venous catheter-related bloodstream infection.

TenNor Therapeutics (6872.HK) was incorporated in 2013 and is a biotech company approaching the commercialization stage, focused on discovering, developing and commercializing differentiated innovative drug products to address unmet clinical needs in bacterial infections and bacteria-related metabolic diseases. Using its independently developed multi-target conjugated molecule technology, it aims to provide optimal treatment options to overcome the limitations of traditional treatments and improve patient outcomes. As of June 30, 2026, the company had built a pipeline of eight innovative programs, including two core products: rifasutenizol (TNP-2198), a multi-target conjugated new molecular entity (NME) candidate used in combination with amoxicillin and a proton pump inhibitor for Helicobacter pylori infection and also as monotherapy for bacterial vaginosis and Clostridioides difficile infection; and rifaquizinone (TNP-2092 injection), a three-target NME candidate for acute bacterial skin and skin structure infections and implant-associated bacterial infections such as prosthetic joint infection, left ventricular assist device infection and central venous catheter-related bloodstream infection.

Focused on bacterial infections and bacteria-related metabolic diseases; patient-demand-oriented development of innovative drugs with genuine clinical value.

• Rifasutenizol (TNP-2198)

  A multi-target conjugated new molecular entity (NME) candidate used in combination with amoxicillin and a proton pump inhibitor for Helicobacter pylori infection, and also as monotherapy for bacterial vaginosis and Clostridioides difficile infection.

• Rifaquizinone (TNP-2092 injection)

  A three-target NME candidate for acute bacterial skin and skin structure infections and implant-associated bacterial infections such as prosthetic joint infection, left ventricular assist device infection and central venous catheter-related bloodstream infection.

1. 1丹诺医药（苏州）股份有限公司tennortherapeutics.com
2. 2丹诺医药（苏州）股份有限公司tennortherapeutics.com
3. 3TenNor Therapeutics (China)wikidata.org